EG433365 inhibitors belong to a class of chemical compounds designed to selectively inhibit a specific target within biological pathways. These inhibitors are characterized by their unique molecular structures, which often feature complex ring systems and functional groups tailored to maximize their binding affinity and selectivity for their target molecule. The chemical backbone of EG433365 inhibitors is typically composed of aromatic or heteroaromatic rings substituted with various moieties that optimize interactions with the active site of their target protein. Such modifications contribute to their potency, enhancing the ability of these molecules to modulate their biological target effectively. They often exhibit high specificity, which is achieved through fine-tuning of hydrogen bonding, hydrophobic interactions, and electrostatic forces, ensuring that the inhibitor fits precisely within the binding pocket of the target. This specificity reduces off-target effects and increases the efficacy of the inhibition.
Structurally, EG433365 inhibitors often incorporate polar and non-polar functional groups to improve their solubility, stability, and bioavailability. These compounds may be synthesized through a variety of chemical routes, allowing for modifications that enhance their physical and chemical properties. The ability to modify the structure of EG433365 inhibitors means that analogs can be developed to improve binding characteristics, optimize pharmacokinetics, and achieve better inhibition profiles. Additionally, the stereochemistry of these molecules plays a crucial role in their activity, as the three-dimensional arrangement of atoms influences their ability to interact with the target. Researchers in the field of chemical biology and drug design find EG433365 inhibitors of particular interest due to their highly specific interactions and the opportunity to manipulate their chemical structure for improved activity and selectivity. This precise interaction between EG433365 inhibitors and their molecular targets makes them valuable tools for studying biological pathways and understanding the molecular mechanisms underpinning various cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Inhibits Teddm1b indirectly by targeting the ERBB signaling pathway. Lapatinib inhibits ERBB1 and ERBB2, disrupting downstream signaling and leading to decreased Teddm1b expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Indirectly inhibits Teddm1b through proteasome inhibition. Bortezomib disrupts proteasomal degradation, leading to the accumulation of ubiquitinated proteins. This includes Teddm1b, resulting in reduced protein levels. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Indirectly inhibits Teddm1b through the retinoic acid signaling pathway. ATRA activates RAR and RXR, leading to transcriptional repression of Teddm1b. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
Inhibits Teddm1b through the Akt/mTOR pathway. MK-2206 inhibits Akt, preventing its activation and downstream mTOR signaling. This leads to decreased translation and reduced expression of Teddm1b. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Indirectly inhibits Teddm1b by inhibiting the proteasome. MG-132 induces the accumulation of ubiquitinated proteins, including Teddm1b, leading to reduced protein levels. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Inhibits Teddm1b indirectly by targeting the MEK/ERK pathway. Trametinib inhibits MEK, preventing ERK activation and downstream signaling. This results in decreased expression of Teddm1b. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Indirectly inhibits Teddm1b by causing DNA damage. Etoposide induces DNA breaks, activating stress responses that downregulate Teddm1b transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Acts as an indirect inhibitor of Teddm1b by targeting the PI3K/Akt/mTOR pathway. LY294002 inhibits PI3K, attenuating Akt/mTOR signaling. This hinders the translation machinery, leading to decreased expression of Teddm1b. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Indirectly inhibits Teddm1b through DNA damage. Cisplatin forms DNA adducts, activating stress responses that downregulate Teddm1b transcription. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Indirectly inhibits Teddm1b by targeting multiple kinases. Sorafenib inhibits kinases upstream of the MAPK and PI3K/Akt/mTOR pathways, resulting in decreased activation of Teddm1b downstream. | ||||||